Mira Pharmaceuticals (MIRA) Cash & Equivalents (2022 - 2025)

Mira Pharmaceuticals (MIRA) has 4 years of Cash & Equivalents data on file, last reported at $6.3 million in Q4 2025.

• Quarterly Cash & Equivalents rose 124.04% year-over-year to $6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (up 124.04% YoY) and the FY2025 annual result came in at $6.3 million, up 124.04% from the prior year.
• Cash & Equivalents advanced to $6.3 million in Q4 2025 per MIRA's latest filing, from $2.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $6.3 million in Q4 2025, with the low at $1349.0 in Q1 2023.
• Average Cash & Equivalents over 4 years is $2.5 million, with a median of $2.6 million recorded in 2025.
• Year-over-year, Cash & Equivalents surged 259351.45% in 2024 and slumped 65.53% in 2025.
• Mira Pharmaceuticals' Cash & Equivalents stood at $350978.0 in 2022, then soared by 1211.35% to $4.6 million in 2023, then slumped by 38.45% to $2.8 million in 2024, then jumped by 124.04% to $6.3 million in 2025.
• Business Quant data shows MIRA's Cash & Equivalents at $6.3 million in Q4 2025, $2.6 million in Q3 2025, and $730475.0 in Q2 2025.